Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression

  • Paola Leporati1,
  • Rodolfo Fonte1,
  • Luca de Martinis1,
  • Alberto Zambelli2,
  • Flavia Magri1,
  • Lorenzo Pavesi2,
  • Mario Rotondi1 and
  • Luca Chiovato1Email author
BMC Cancer201515:397

https://doi.org/10.1186/s12885-015-1400-0

Received: 13 May 2014

Accepted: 29 April 2015

Published: 12 May 2015

Abstract

Background

Acromegaly is a rare disease associated with an increased risk of developing cancer.

Case presentation

We report the case of a 72-year-old man who was diagnosed with acromegaly (IGF-1 770 ng/ml) and breast cancer. Four years before he suffered from a colon-rectal cancer. Pituitary surgery and octreotide-LAR treatment failed to control acromegaly. Normalization of IGF-1 (97 ng/ml) was obtained with pegvisomant therapy. Four years after breast cancer surgery, 2 pulmonary metastases were detected at chest CT. The patient was started on anastrozole, but, contrary to medical advice, he stopped pegvisomant treatment (IGF-I 453 ng/ml). Four months later, chest CT revealed an increase in size of the metastatic lesion of the left lung. The patient was shifted from anastrozole to tamoxifen and was restarted on pegvisomant, with normalization of serum IGF-1 levels (90 ng/ml). Four months later, a reduction in size of the metastatic lesion of the left lung was detected by CT. Subsequent CT scans throughout a 24-month follow-up showed a further reduction in size and then a stabilization of the metastasis.

Conclusions

This is the first report of a male patient with acromegaly and breast cancer. The clinical course of breast cancer was closely related to the metabolic control of acromegaly. The rapid progression of metastatic lesion was temporally related to stopping pegvisomant treatment and paralleled a rise in serum IGF-1 levels. Normalization of IGF-1 after re-starting pegvisomant impressively reduced the progression of metastatic breast lesions. Control of acromegaly is mandatory in acromegalic patients with cancer.

Keywords

Acromegaly Tamoxifen Pegvisomant Breast cancer

Background

Acromegaly is a chronic disease caused by excessive growth hormone (GH) secretion by a GH-secreting pituitary adenoma. Acromegalic patients suffer from high morbidity and mortality mainly due to cardiovascular, metabolic and respiratory diseases [1, 2]. The risk of developing malignancies is also increased in acromegalic patients [3]. However, cancer-related mortality is increased only in acromegalic patients with poorly controlled disease, as assessed by high circulating levels of Insulin-like-Growth-Factor 1 (IGF-1) [4, 5]. Cancers of the thyroid, breast and colon-rectum are the most commonly encountered malignancies in patients with acromegaly [68]. Thus, screening for tumors is recommended before, during and after treatment for acromegaly [6]. Long term follow up is also mandatory, mainly in patients who, despite treatment, fail to achieve a good metabolic control, as assessed by persistently elevated serum levels of IGF-1.

Male breast cancer is a rare malignancy that accounts for 0.7 % of all breast cancers [9] and displays a significant geographic variation in its incidence [10]. The mean age at diagnosis is in the fifth decade [9] and the prognosis is generally worse than in women [11]. Several factors including obesity, chronic liver disease, genetics, and family history were reported to be implicated in the development of the disease [12].

We hereby report the case of a patient who was diagnosed with acromegaly and breast cancer. Four years before he had been successfully treated for a colon-rectal cancer. To the best of our knowledge, this is the first report of a male patient with acromegaly who developed breast cancer. In our opinion, relevant clinical and therapeutic information can be drawn from the behavior of breast cancer in relation to the metabolic control of acromegaly.

Case presentation

A 72-years-old male patient was referred to our Unit in May 2007 for a non-toxic multinodular goiter, which had recurred following a partial thyroidectomy performed nearly 20 years before. The clinical history of the patients revealed: 1) Type two diabetes mellitus, which had been diagnosed at the age of 50 years and was treated with insulin and oral glucose-lowering drugs; 2) Hypertension since the age of 44 years, complicated by retinopathy; 3) a previous (four years before) diagnosis of colon-rectal adenocarcinoma (G2, without sub-serosal infiltration), which had been treated with surgical resection (right colectomy with ileo-colic anastomosis) and adjuvant chemotherapy. Resection margins were free of disease and surrounding lymph nodes were not involved. In the subsequent follow-up, no local relapse or metastatic spread was detected.

When first seen in our clinic, broad hands and feet were evident, which were reported to have increased in size over the years. Physical examination also revealed coarse facial features, enlargement of the nose, lips and ears, pronounced jaw with attendant macroglossia and teeth gapping, generalized thickening of the skin. Weight was 78 kg and height 172 cm, for a BMI of 26.36 kg/m2. Blood tests showed high levels of GH (85.9 ng/ml). Serum IGF-1 was much higher (770 ng/ml) than the expected elderly normal range (87–177 ng/ml). The serum levels of IGF-1 during the whole follow-up are illustrated in Fig. 1. The remaining pituitary hormones were within the normal range [Table 1] with the exception of a slightly elevated serum prolactin (30.8 μUI/ml. A diagnosis of active acromegaly was made. Pituitary MRI showed a macroadenoma (20 mm in maximum diameter). The sella turcica floor was depressed and the pituitary stalk was displaced. The patient refused surgery, and therapy with octreotide LAR (30 mg every 28 days) was started. Further diagnostic work-up revealed heart abnormalities (fibrosclerotic thickening of the mitral and aortic valve with mild aortic insufficiency) and prostate hypertrophy. Thyroid ultrasound confirmed a relapsing multinodular goiter (estimated thyroid volume: 89 ml). Fine needle aspiration cytology of the main thyroid nodules was consistent with benign lesions. Physical examination also revealed a firm nodule of the left breast (upper-outer quadrant) with palpable axillary nodes. Cytological examination of the breast lesion was diagnostic for malignancy. In June 2007, the patient underwent radical breast surgery. 12 lymph-nodes were surgically removed from the axillary region. At histology breast cancer was a hormone-sensitive (ER+ 70 %, PR+ 20 %), in situ ductal breast carcinoma with micro-infiltrating spots (<1 mm), (pT1mic, pN0M0 G2, Ki67 10 %, c-erb B2 DAKO HerceptTest 1+ neg). All examined lymph-nodes were free of metastatic involvement. The contralateral breast was evaluated by physical examination and ultrasound. A synchronous breast cancer was excluded. A detailed family history was also collected, which was negative for the presence of either breast or ovary cancer. The patient received post-surgical radiotherapy (50 Gy in the left mammary region) with no adjuvant systemic treatment.
Fig. 1

Serum levels of IGF-1 in relation to acromegaly control and breast cancer evolution. The dotted line represents the upper normal limit for IGF-I, 1. May 2007: Diagnosis of acromegaly (start of octreotide LAR treatment), 2. June 2007: Surgery for breast cancer, 3. February 2008: Trans-sphenoidal adenomectomy, 4. June 2009: Octreotide LAR withdrawal, start pegvisomant, 5. December 2010- January 2011: Diagnosis of lung metastasis of breast cancer, 6. February 2011: Start anastrazol and spontaneous pegvisomant withdrawal, 7. June 2011: Anastrazol withdrawal, start tamoxifen, 8. July 2011: Re-start pegvisomant, 9. September 2011: Reduction in diameter of pulmonary lesions

Table 1

Hormonal findings at diagnosis of acromegaly

Parameters

Patient values

Normal values

GH (ng/ml)

85.9

<=1

IGF-I (ng/ml)

770

87–177

Prolactin (mcUI/ml)

30.8

2.5–17

ACTH (pg/ml)

33.3

0–71

Cortisol (mcg/dl)

16.7

5–23.3

TSH (mIU/l)

0.857

0.4–4

FT4 (ng/dL)

0.91

0.8–1.9

FT3 (pg/mL)

2.46

1.8–4.2

Tg Ab (IU/ml)

12.6

<60

TPO Ab (IU/ml)

13.7

<60

FSH (mIU/ml)

7.94

0.7–11.1

LH (mIu/ml)

2.67

0.8–7.6

Testosterone (ng/dl)

246

181–758

In February 2008, ten months after starting octreotide LAR, the serum levels of IGF-1 were still high (531 ng/ml) and the patient accepted to undergo trans-sphenoid surgery. Histological examination confirmed a somatothrope-cell pituitary adenoma. Immediately after pituitary surgery the IGF-1 serum levels decrease (192 ng/ml). Two months later, the IGF-1 serum levels raised again (372 ng/ml), which was consistent with the discovery of residual adenomatous tissue at pituitary MRI. Octreotide LAR treatment was re-instituted. 17 months after surgery, due to inadequate control of acromegaly on octreotide LAR (January 2009: GH = 7.5 ng/ml, IGF-1 = 292 ng/ml; July 2009: IGF-I = 231 ng/ml), pegvisomant (10 mg/day) treatment was started. Two months later, normal levels of serum IGF-I (97 ng/ml) were obtained.

In December 2010 a standard X-ray and a CT of the chest showed a metastatic lesion located in the lower lobe of the right lung, with a maximum diameter of 2.5 cm. A second metastatic lesion was evident in the apical segment of the lower lobe of the left lung (maximum diameter = 1.5 cm) [Fig. 2: Panel a]. The patient underwent right lower lobectomy. Histological examination confirmed the presence of a neoplastic nodule, which was diagnosed as metastatic breast cancer (ER+, Mammoglobin+). Hormone therapy with anastrozole (1 mg/day) was started. Meanwhile, contrary to the medical advice, the patient stopped pegvisomant treatment. IGF-1 serum levels increased again (453 ng/ml). In June 2011, progression of the metastatic lesion in the lower lobe of the left lung (from 1.5 cm to 2 cm maximum diameter) was observed at chest CT [Fig. 2: Panel b]. Two months later, a widespread metastatic disease of bone was detected at PET-FDG. Due to the neoplastic progression, the patient was shifted from Anastrazol to Tamoxifen (20 mg/day) treatment. In July 2011, the patient was re-started on pegvisomant treatment (10 mg/day), which led to a normalization of serum IGF-1 levels (90 ng/ml). A further chest CT was performed in September 2011 and displayed a significant reduction in size of the left lung metastasis (1.5 cm maximum diameter) [Fig. 2: Panel c]. In April 2012 this lung metastasis was found to be smaller than in the previous CT (1.1 cm of maximum diameter). Subsequent CT scans, performed 6, 12 and 20 months later [Fig. 2: Panel d], showed no progression of the metastatic lung disease. The patient remains in fair clinical conditions, has a good control of acromegaly (January 2014: IGF-1 = 76 ng/ml) and his treatment still includes pegvisomant for acromegaly and tamoxifen for metastatic breast cancer.
Fig. 2

CT scan of the chest showing the radiological history of the metastatic lesion located in the apical segment of the lower lobe of the left lung. Panel a (01/2011): first evidence (maximum diameter 1.5 cm). Panel b (5/2011): dimensional increase after pegvisomant withdrawal (maximum diameter 2 cm). Panel c (09/2011): dimensional shrinkage after pegvisomant restart (maximum diameter 1.5 cm). Panel d (01/2014): further dimensional shrinkage under pegvisomant treatment (maximum diameter 1.1 cm)

Conclusions

We report the case of a caucasian male patient who initially suffered from colorectal cancer and subsequently was diagnosed with acromegaly and breast cancer. Acromegaly was not cured by trans-sphenoidal surgery, was partially resistant to octreotide LAR and was successfully controlled by pegvisomant treatment, as assessed by IGF-1 serum measurements. Clinically relevant changes in the progression of breast cancer and metastatic lesions were observed in relation to the metabolic control of acromegaly. A few peculiar aspects deserve discussion.

First, the patient was a man and, to the best of our knowledge, there is no previous description of a male patient with acromegaly and breast cancer. Even in the largest series of male patients with breast cancer [13], the Authors did not report a case associated with acromegaly. Although a single observation does not allow establishing a causal link between the two pathologic conditions, the fact that both acromegaly (40–90 cases/million/year) and male breast cancer (10 cases/million/year) are rare diseases argues against a chance association. Although the mechanisms by which acromegaly results in an increased risk of cancer have not been fully clarified, in vitro studies demonstrated that GH and IGF-1 have a proliferative and anti-apoptotic effect on different cell lines, eventually leading to neoplastic evolution [14]. Moreover, high serum levels of GH and IGF-1 enhance the proliferation rate of epithelial cells of the sigma crypts, which, by increasing the length of colon and sigma, would predispose to the development of colon-rectal cancer [15]. IGF-1, after binding to its receptor, is also known to increase the proliferation rate of estrogen-dependent breast cancer cell lines. Based on the above evidence, the co-existence of breast cancer and acromegaly might not be surprising. Given the long history of acromegaly, it also conceivable to believe that in our patient a cause effect relationship could exist between the endocrine disease and colon-rectal cancer. A genetic background linking GH secreting pituitary adenomas, colon-rectal cancer and breast cancer might also be hypothesized. In a study by Georgitsi et al., the Authors evaluated the role of AIP mutations, which are known to occur in pituitary adenomas, in the genesis of common cancers (prostate, breast and colon-rectal cancer). However, no AIP mutation could be detected in these types of cancer. To our knowledge, no other study evaluated the existence of genetic link between acromegaly, colon-rectal and breast cancer [16].

Second, the aggressive behavior of breast cancer was unexpected in this patient, due to the favorable prognostic TNM stage at diagnosis (pT1a mic, N0). Also intriguing is the observation that the metastatic progression of breast cancer was temporally related to the interruption of pegvisomant treatment. Due to the lack of proper investigations, we cannot make any speculation about the association between acromegaly control and the onset of breast cancer metastasis. However, on the other hand, the rapid spread of the metastatic lesions occurred concomitantly to a rise in serum IGF-1 levels. The subsequent normalization of IGF-1, due to the re-introduction of pegvisomant treatment, was followed by a reduction in size and a stabilization of the lung metastasis. This sequence of events is in agreement with the observations of Chae et al. [17], who reported an impressive amelioration of metastatic breast cancer in a female patient with acromegaly being treated with octreotide LAR. At variance with octreotide LAR, in vivo data on the anti-cancer effect of pegvisomant are scanty. Yin et al. demonstrated that pegvisomant is more effective than octreotide LAR in suppressing the GH-IGF-1 axis, thus implying that this GH-receptor blocker drug could be effective in treating several types of tumors, such as breast and colon-rectal cancers [18].

The apparent failure of the elective treatment with anastrozole and the favorable response to tamoxifen could be explained by several factors. Previous studies demonstrated that cross talks between the signaling pathways of estrogen receptor (ER) and IGF-1 receptor (R) play a crucial role in determining resistance to anti-estrogen endocrine therapy in breast cancer [1921]. In vitro experiments by Lisztwan et al. demonstrated that adding the aromatase blocker letrozole to an inhibitor of the IGF-1 R pathway synergistically blocks the proliferation and induces apoptosis of breast cancer cells [22]. Taken together, these findings would suggest that a dual targeting of IGF-1 R and ER pathways would prevent or delay the onset of endocrine resistance. At variance with this assumption, a randomized, open-label, phase III trial reported similar event-free, recurrence-free, and overall survival in 667 postmenopausal women with ER-positive early-stage breast cancer who received treatment with tamoxifen or tamoxifen + octreotide LAR as adjuvant therapy [23]. However, these negative findings were obtained in patients with normal GH and IGF-1, a completely different clinical situation from that of our acromegalic patient who, due to the high levels of circulating IGF-1, had a strong activation of the IGF-1-R pathway. In turn, this IGF-1 R activation could explain the apparent resistance to anastrozole and the benefits observed with tamoxifen. Indeed, anastrozole was administered when the circulating levels of IGF-1 were high due to the interruption of pegvisomant treatment, while the shift to tamoxifen coincided with re-starting pegvisomant and the subsequent metabolic control of acromegaly. Moreover, tamoxifen itself might have been responsible for a further reduction of IGF-1 serum levels. This IGF-1 lowering effect of tamoxifen was previously described both in acromegalic patients and in healthy subjects [2427].

In conclusion, we report for the first time the case of a male acromegalic patient with breast cancer. The clinical evolution of breast cancer in our patient highlights the concept that the control of acromegaly might play a role in the outcome of the coexistent neoplasia. No matter how the control of acromegaly is achieved, suppression of IGF-1 should be mandatory in acromegalic patients with cancer.

Consent

Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Declarations

Authors’ Affiliations

(1)
Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri I.R.C.C.S., Laboratory for Endocrine Disruptors, Chair of Endocrinology
(2)
Unit of Medical Oncology, Fondazione Salvatore Maugeri I.R.C.C.S.

References

  1. Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord. 2008;9:33–9.View ArticlePubMedGoogle Scholar
  2. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol. 2004;151:439–46.View ArticlePubMedGoogle Scholar
  3. Kauppinen-Mäkelin R, Sane T, Välimäki MJ, Markkanen H, Niskanen L, Ebeling T, et al. Increased cancer incidence in acromegaly - a nationwide survey. Clin Endocrinol (Oxf). 2010;72:278–9.View ArticleGoogle Scholar
  4. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab. 1998;83:2730–4.PubMedGoogle Scholar
  5. Kauppinen-Mäkelin R, Sane T, Reunanen A, Välimäki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Meta. 2005;90:4081–6.View ArticleGoogle Scholar
  6. Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord. 2008;9:41–58.View ArticlePubMedGoogle Scholar
  7. Dworakowska D, Gueorguiev M, Kelly P, Monson JP, Besser GM, Chew SL, et al. Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines. Eur J of Endocrinol. 2010;163:21–8.View ArticleGoogle Scholar
  8. Tita P, Ambrosio MR, Scollo C, Carta A, Gangemi P, Bondanelli M, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf). 2005;63:161–7.View ArticleGoogle Scholar
  9. Giordano SH. A review of diagnosis and management of male breast cancer. Oncologist. 2005;10:471–9.View ArticlePubMedGoogle Scholar
  10. Field KM, Campbell B, De Boer R. Male breast cancer: Progress, prognosis and future pathways. Asia Pac J Clin Oncol. 2008;4:6–17.View ArticleGoogle Scholar
  11. Hinrichs CS, Watroba NL, Rezaishiraz H, Giese W, Hurd T, Fassl KA, et al. Lymphedema secondary to postmastectomy radiation: Incidence and risk factors. Ann Surg Oncol. 2004;11:573–80.View ArticlePubMedGoogle Scholar
  12. Contractor KB, Kaur K, Rodrigues GS. Male breast cancer: is the scenario changing? World J Surg Oncol. 2008;6:58.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Shah S, Bhattacharyya S, Gupta A, Ghosh A, Basak S. Male breast cancer: a clinicopathologic study of 42 patients in eastern India. Indian J Surg Oncol. 2012;3:245–9.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102–52.View ArticlePubMedGoogle Scholar
  15. Cats A, Dullaart RP, Kleibeuker JH, Kuipers F, Sluiter WJ, Hardonk MJ, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;1:523–6.Google Scholar
  16. Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K, Vahteristo P, et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer. 2007;96:352–6.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, et al. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol. 2013;31:398–400.View ArticleGoogle Scholar
  18. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res. 2007;13:1000–9.View ArticlePubMedGoogle Scholar
  19. Dickler MN. Targeting the insulin-like growth factor pathway in Estrogen receptor-positive breast cancer: a bumpy start with an uncertain future. J Clin Oncol. 2011;29:3846–8.View ArticlePubMedGoogle Scholar
  20. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res. 2007;13:1950–4.View ArticlePubMedGoogle Scholar
  21. Fagan DH, Yee DJ. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:423–9.View ArticlePubMedGoogle Scholar
  22. Lisztwan J, Pornon A, Chen B, Chen S, Evans DB. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res. 2008;10:R56.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29:3869–76.View ArticlePubMedGoogle Scholar
  24. Maiza JC, Castillo-Ros S, Matta M, Bennet A, Caron P. Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide. Pituitary. 2012;15:23–7.View ArticleGoogle Scholar
  25. Cozzi R, Attanasio R, Oppizzi G, Orlandi P, Giustina A, Lodrini S, et al. Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest. 1997;20:445–51.View ArticlePubMedGoogle Scholar
  26. Colletti RB, Roberts JD, Devlin JT, Copeland KC. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res. 1989;49:1882–4.PubMedGoogle Scholar
  27. Balili I, Barkan A. Tamoxifen as a therapeutic agent in acromegaly. Pituitary. 2014;17:500–4.View ArticlePubMedGoogle Scholar

Copyright

© Leporati et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement